FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017018324> ?p ?o ?g. }

• W2017018324 endingPage "61" @default.
• W2017018324 startingPage "257" @default.
• W2017018324 abstract "For patients with refractory bone and soft tissue sarcoma (STS), treatment options have been limited. Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity. The aim of this retrospective study was to evaluate the response rate, progression-free survival (PFS), progression-free rate (PFR), and median duration of response to high-dose ifosfamide (HDI) as at least second-line chemotherapy for patients with advanced bone sarcoma and STS.Thirty metastatic, unresectable sarcoma patients who were treated with HDI chemotherapy between May 1999 and November 2007 were included in the analysis. In total, 106 cycles (median 3 cycles; range 1-8 cycles) were administered. Twenty-one patients received treatment as second-line chemotherapy, and 9 patients as third-line treatment. HDI was given at a dose of 2 g/m(2) over 3 h, and at a dose of 2 g/m(2) per day; continuous infusion was administered on 6 consecutive days (2 g/m(2)/6 days) every 3 weeks.After a median follow-up of 49 months (range 10-114), median PFS was 2.9 months (range 0.4-9.3) and median overall survival 8.7 months (range 0.4-57.8). The 3- and 6-month PFR were 47% (SE 9.1%) and 20% (SE 7.3%), respectively. Median response duration of HDI was 2.9 months (range 0.7-7.6). Of the 28 evaluable patients, 2 (7%) achieved complete response, 5 (18%) partial response, and 4 (14%) stable disease, and overall disease control was 39%. Two responders out of 7 (28.5%) and 4 patients out of 11 (36%) with controlled disease by HDI had a synovial sarcoma. Two patients were not evaluable because they were switched to another treatment due to ifosfamide-induced encephalopathy. Grade 3-4 neutropenia was seen in 13 (43%) patients, and treatment-related death was observed in one patient.HDI at a total dose of 14 g/m(2) with mesna is still an active salvage regimen, particularly in patients with synovial sarcomas." @default.
• W2017018324 created "2016-06-24" @default.
• W2017018324 creator A5002680076 @default.
• W2017018324 creator A5012507797 @default.
• W2017018324 creator A5018855985 @default.
• W2017018324 creator A5019406140 @default.
• W2017018324 creator A5045587524 @default.
• W2017018324 creator A5047808702 @default.
• W2017018324 creator A5077563153 @default.
• W2017018324 date "2011-01-01" @default.
• W2017018324 modified "2023-10-11" @default.
• W2017018324 title "High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients." @default.
• W2017018324 cites W1883812557 @default.
• W2017018324 cites W1901845528 @default.
• W2017018324 cites W1903528106 @default.
• W2017018324 cites W1909085795 @default.
• W2017018324 cites W1972036916 @default.
• W2017018324 cites W1975828433 @default.
• W2017018324 cites W1984819380 @default.
• W2017018324 cites W1992258393 @default.
• W2017018324 cites W1997197477 @default.
• W2017018324 cites W2043103956 @default.
• W2017018324 cites W2047664336 @default.
• W2017018324 cites W2057195209 @default.
• W2017018324 cites W2057625683 @default.
• W2017018324 cites W2077274936 @default.
• W2017018324 cites W2090614481 @default.
• W2017018324 cites W2091453908 @default.
• W2017018324 cites W2107078868 @default.
• W2017018324 cites W2129148702 @default.
• W2017018324 cites W2145828205 @default.
• W2017018324 cites W2157598836 @default.
• W2017018324 cites W2160752563 @default.
• W2017018324 cites W2169512039 @default.
• W2017018324 cites W2254006519 @default.
• W2017018324 cites W4211207176 @default.
• W2017018324 doi "https://doi.org/10.1159/000328795" @default.
• W2017018324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21734417" @default.
• W2017018324 hasPublicationYear "2011" @default.
• W2017018324 type Work @default.
• W2017018324 sameAs 2017018324 @default.
• W2017018324 citedByCount "25" @default.
• W2017018324 countsByYear W20170183242012 @default.
• W2017018324 countsByYear W20170183242013 @default.
• W2017018324 countsByYear W20170183242014 @default.
• W2017018324 countsByYear W20170183242016 @default.
• W2017018324 countsByYear W20170183242017 @default.
• W2017018324 countsByYear W20170183242018 @default.
• W2017018324 countsByYear W20170183242019 @default.
• W2017018324 countsByYear W20170183242020 @default.
• W2017018324 countsByYear W20170183242021 @default.
• W2017018324 countsByYear W20170183242022 @default.
• W2017018324 countsByYear W20170183242023 @default.
• W2017018324 crossrefType "journal-article" @default.
• W2017018324 hasAuthorship W2017018324A5002680076 @default.
• W2017018324 hasAuthorship W2017018324A5012507797 @default.
• W2017018324 hasAuthorship W2017018324A5018855985 @default.
• W2017018324 hasAuthorship W2017018324A5019406140 @default.
• W2017018324 hasAuthorship W2017018324A5045587524 @default.
• W2017018324 hasAuthorship W2017018324A5047808702 @default.
• W2017018324 hasAuthorship W2017018324A5077563153 @default.
• W2017018324 hasConcept C121332964 @default.
• W2017018324 hasConcept C126322002 @default.
• W2017018324 hasConcept C126894567 @default.
• W2017018324 hasConcept C136948725 @default.
• W2017018324 hasConcept C141071460 @default.
• W2017018324 hasConcept C142424586 @default.
• W2017018324 hasConcept C142724271 @default.
• W2017018324 hasConcept C2776694085 @default.
• W2017018324 hasConcept C2777506904 @default.
• W2017018324 hasConcept C2778119113 @default.
• W2017018324 hasConcept C2778256501 @default.
• W2017018324 hasConcept C2778629024 @default.
• W2017018324 hasConcept C2778822529 @default.
• W2017018324 hasConcept C71924100 @default.
• W2017018324 hasConcept C87355193 @default.
• W2017018324 hasConcept C90924648 @default.
• W2017018324 hasConceptScore W2017018324C121332964 @default.
• W2017018324 hasConceptScore W2017018324C126322002 @default.
• W2017018324 hasConceptScore W2017018324C126894567 @default.
• W2017018324 hasConceptScore W2017018324C136948725 @default.
• W2017018324 hasConceptScore W2017018324C141071460 @default.
• W2017018324 hasConceptScore W2017018324C142424586 @default.
• W2017018324 hasConceptScore W2017018324C142724271 @default.
• W2017018324 hasConceptScore W2017018324C2776694085 @default.
• W2017018324 hasConceptScore W2017018324C2777506904 @default.
• W2017018324 hasConceptScore W2017018324C2778119113 @default.
• W2017018324 hasConceptScore W2017018324C2778256501 @default.
• W2017018324 hasConceptScore W2017018324C2778629024 @default.
• W2017018324 hasConceptScore W2017018324C2778822529 @default.
• W2017018324 hasConceptScore W2017018324C71924100 @default.
• W2017018324 hasConceptScore W2017018324C87355193 @default.
• W2017018324 hasConceptScore W2017018324C90924648 @default.
• W2017018324 hasIssue "3-4" @default.
• W2017018324 hasLocation W20170183241 @default.
• W2017018324 hasLocation W20170183242 @default.
• W2017018324 hasOpenAccess W2017018324 @default.
• W2017018324 hasPrimaryLocation W20170183241 @default.

• next